Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), ...

Edwards Lifesciences (NYSE:EW) today shared new data for its Evoque transcatheter tricuspid valve replacement (TTVR) system.

They look to establish minimum volumes for hospitals and operators seeking to start and maintain TTVI programs.

Abbott (NYSE:ABT) said a new clinical trial demonstrated the reduction in heart failure hospitalization (HFH) risk with its TriClip system.

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received optimal medical therapy plus a minimally invasive procedure using a clip to repair the valve ...

Edwards Lifesciences has received US Food and Drug Administration (FDA) approval for its Evoque tricuspid valve replacement system, which becomes the first transcatheter therapy to be approved in the ...

UC San Francisco interventional cardiologists and interventional echocardiographers recently performed the health system’s first commercial transcatheter tricuspid valve replacement procedure using ...

LONDON, England—There are more positive signs that current-generation transcatheter valves, originally designed to treat tricuspid aortic stenosis (AS), do just fine in the setting of bicuspid disease ...

Edwards Lifesciences has claimed the FDA’s first approval of a transcatheter replacement implant for a leaky tricuspid heart valve, three months after garnering a green light in Europe. The Evoque, ...

A new study into the causes of leakage in one of the heart's most complex valve structures could lead to improved diagnosis and treatment of the condition. An estimated 1.6 million Americans suffer ...

An estimated 1.6 million Americans suffer moderate to severe leakage through their heart's tricuspid valve, but what causes the problem is not well understood. A new study found that either dilating ...